Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

John Abramson

John Abramson

John Abramson, MD, MSc, was family physician for more than 20 years. He is now a Lecturer in Healthcare Policy at Harvard Medical School and serves as a consultant to plaintiffs’ attorneys in litigation involving pharmaceuticals and medical devices, including cases involving statins.

Recent stories

  • Illustration of a heart inside a pill bottle

    Cholesterol-lowering statin therapy for healthy people is not as simple as 'yes' or 'no'Subscription

    7 MAR 2017

    Recent reports of large trials extolling the virtues of statins have led many to believe that low-risk patients should take them, but an examination of the evidence provides food for thought.

  • Article on statin safety makes unproven assertionsSubscription

    14 OCT 2016

    With publication of the review article in The Lancet on 8 September 2016 looking at the efficacy and safety of statin therapy, the pressure on GPs to prescribe high-intensity statins to low-risk people has become even greater. Under the heading ‘Proven beneficial effects of statin therapy’, the review states: “Lowering low-density lipoprotein (LDL) cholesterol by 2mmol/L with an effective statin regimen for about five years in 10,000 patients would typically prevent major vascular ev

  • Statins have been overprescribed for decades for many different reasons. Now is the time to reverse the trend

    Prescribing statins: time to rein it inSubscription

    19 MAR 2015

    Statins have been overprescribed for decades for many different reasons. Now is the time to reverse the trend.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.